Epigenetics

Epigenetics is the control of gene expression without altering the DNA sequence, including DNA methylation, genomic imprinting, maternal effects, gene silencing, nucleolus dominant, dormant transposon activation, and RNA editing. In contrast to classical genetics, which focuses on the effects of gene sequences on biological functions, epigenetics focuses on the mechanisms by which these "epigenetic phenomena" are established and maintained.

Cat. No.	Product name
BP13976	KHK-IN-2
BP13976	KHK-IN-2 is a selective and potent ketohexokinase (KHK) inhibitor with an IC50 of 0.45 μM.
BP13975	Kgp-IN-1
BP13975	Kgp-IN-1 is an arginine-specific gingipain (Rgp) inhibitor.
BP13974	KG-501
BP13974	KG-501 is a cAMP response element-binding protein (CREB) inhibitor(IC50 : 6.89 μM).
BP13973	KF21213
BP13973	KF21213 shows a high affinity for the adenosine A2A receptors (Ki=3.0 nM). KF21213 is a highly selective ligand for mapping CNS adenosine A2A receptors.
BP13972	KF 13218
BP13972	KF 13218 is a selective, potent and long lasting thromboxane B2 (TXB2) synthase inhibitor with an IC50 value of 5.3±1.3 nM.
BP13971	KDM5-IN-1
BP13971	KDM5-IN-1 is an effective and selective inhibitor of KDM5 with an IC50 of 15.1 nM.
BP13970	KDM5-C70
BP13970	KDM5-C70 is an ethyl ester derivative of KDM5-C49. KDM5-C70 is an effective, cell-permeable, and pan-KDM5 histone demethylase inhibitor. KDM5-C70 has an antiproliferative effect in myeloma cells, inducing a genome-wide elevation of H3K4me3 levels.
BP13969	KDM5A-IN-1
BP13969	KDM5A-IN-1 is a potent and orally bioavailable inhibitor of pan-histone lysine demethylases 5 (IC50s: 45 nM, 56 nM, and 55 nM for KDM5A, KDM5B, and KDM5C) and (EC50: 960 nM for PC9 H3K4Me3). KDM5A-IN-1 is obviously less effective against other KDM5B enzymes (1A, 2B, 3B, 4C, 6A, 7B).
BP13968	KDM4D-IN-1
BP13968	KDM4D-IN-1 is a KDM4D inhibitor (IC50: 0.41±0.03 μM).
BP13967	Kazinol A
BP13967	Kazinol A shows strong inhibition of arachidonic acid (AA)-induced platelet aggregation. It also exhibits potent inhibition with IC50 values ranging 0.6-164 M against XOD. Kazinol A may be a candidate for the development of effective anti-cancer drug on human urinary bladder cancer, it induces cytotoxic effects in human bladder cancer cells, including the cisplatin-resistant T24R2.
BP13966	KA2507
BP13966	KA2507 is a potent and selective HDAC6 inibitor with an IC50 of 2.5nM.
BP13965	K-252c
BP13965	K-252c is a staurosporine analog isolated from Nocardiopsis sp. and is a cell-permeable PKC inhibitor (IC50: 2.45 μM). K-252c also inhibits β-lactamase, chymotrypsin, and malate dehydrogenase. K-252c causes apoptosis in human chronic myelogenous leukemia cancer cells.
BP13964	K-252b
BP13964	K-252b is an indolocarbazole isolated from the actinomycete Nocardiopsis and is a PKC inhibitor. K-252b can be used to inhibit extracellular kinases of cells in culture because it can’t pass through the cell membrane freely.
BP13963	K00135
BP13963	K00135 is a selective inhibitor of Pim kinases and can be used in studies about gastric cancer and antileukemic therapeutics.
BP13962	JW 55
BP13962	JW 55 is an effective and selective β-catenin signaling pathway inhibitor, works by inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2).
BP13961	JQKD82
BP13961	JQKD82 is a selective inhibitor of KDM5 and increases H3K4me3. JQKD82 can be used in studies about the treatment of multiple myeloma.
BP13960	JQEZ5
BP13960	JQEZ5 is an inhibitor of EZH2 lysine methyltransferase (IC50 = 11.1 nM).
BP13959	JQ-1 (carboxylic acid)
BP13959	JQ-1 carboxylic acid is a cell-permeable BRD4 inhibitor with IC50s of 77 nM for BRD4(1) and 33 nM for BRD4(2)
BP13958	JNJ-64619178
BP13958	JNJ-64619178 is a selective, orally active, and pseudo-irreversible inhibitor of protein arginine methyltransferase 5 (IC50: 0.14 nM). It has effective activity In lung cancer.
BP13957	JNJ-42041935
BP13957	JNJ-42041935 is a potent (pKi = 7.3-7.9), 2-oxoglutarate competitive, reversible, and selective inhibitor of PHD enzymes.